Forgot Password?
Return to Course Listing

CME: Chronic inflammatory demyelinating polyneuropathy (CIDP): Optimizing pharmacotherapeutic management strategies

Activity Description / Statement of Need:

In this online self-learning program:

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Occurring at an incidence of 4-9 people per 100,000, CIDP most commonly occurs in adults aged of 40 to 60, although it may also occur in children and the elderly. The pathophysiology of CIDP is not completely understood but involves several humoral and cell-mediated mechanisms. Symptoms of CIDP include progressive limb weakness, usually with a predilection for proximal muscles, and sensory loss and are monophasic and progress for 8 weeks or more.

Target Audience:

Healthcare professionals specializing in: neurology, internal medicine; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in neurology; and those who otherwise commonly care for or clinically encounter patients with CIDP.


This program is supported by an educational grant from CSL Behring.

This activity is free of charge.


Release Date: July 15, 2020 -- Expiration Date: July 15, 2022

Faculty: Tahseen Mozaffar, MD

Agenda

Faculty introduction, disclosures

Introduction content

  • Pathophysiology and presentation of CIDP
  • Incidence and prevalence
  • Misdiagnosis and differential diagnoses

Diagnosis and treatment of CIDP

  • Currently available clinical guidelines (EFNS/PNS)
  • Diagnosis of CIDP: Electrodiagnostic criteria
  • Diagnostic support: Lab evaluation, nerve imaging
  • Currently available treatment options (immunoglobulin, corticosteroids, plasma exchange)
  • Long-term maintenance of CIDP with immunoglobulin therapy
  • Recent research into subcutaneous immunoglobulin

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the common clinical characteristics of CIDP.
  • Identify components of electrodiagnostic criteria used to diagnose CIDP.
  • Evaluate the present treatment options currently available for the management of CIDP.
  • Identify new and emerging therapies for the treatment of CIDP.

Accreditation

ACCME Activity #201861259

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosures: Tahseen Mozaffar, MD, Professor of Neurology and Pathology & Lab Medicine, Interim Chair, Department of Neurology, University of California, Irvine, has received advisory board and/or research funding from Abbvie, Alexion, Amicus, Argenx, Audentes, Sanofi-Genzyme, Sarepta, Spark Therapeutics, Myositis Association, the Muscular Dystrophy Association, the National Institutes for Health, Bristol-Myers-Squib, Cartesian Therapeutics, Grifols, Momenta, Ra Pharmaceuticals, Sanofi-Genzyme, UCB, and Valerion.

Disclosures of Educational Planners: Charles Turck, Pharm, DBCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from CSL Behring.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care

Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies

Migraine Updates from the American Headache Society Annual Meeting (AHS 2020)

Parkinson's disease: Optimizing pharmacotherapeutic management strategies and addressing clinical challenges